Xiaopeng Tang

Prof. Dr. Xiaopeng Tang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 February 2025 in Blood
Verified
Journal Article
Open access
MXMin Xue
Min Xue
SWShaoying Wang
Shaoying Wang
CLChangjiang Li
Changjiang Li
YWYuewei Wang
Yuewei Wang
MLMing Liu
Ming Liu
XTXiaopeng Tang
Xiaopeng Tang
Coagulation is related to inflammation, but the key pathway, especially innate immune system and coagulation regulation, is not well understood and need to be further explored. Here, we demonstrated that neutrophil gelatinase-associated lipocalin (NGAL), an innate immune inflammatory mediator, is upregulated in patients with thrombosis. Furthermore, it contributes to the initiation and amplification of coagulation, hemostasis, and thrombosis. This occurs by enhancing tissue factor expression on the cell surface, potentiating various clotting factors such as thrombin, kallikrein, factor XIa (FXIa), and FVIIa, promoting thrombin-induced platelet aggregation, and inhibiting antithrombin. NGAL knockout led to strikingly prolonged clot reaction time and kinetic time in thromboelastography analysis, along with reduced thrombus generation angle and lower thrombus maximum amplitude, which were in line with remarkably prolonged activated partial thromboplastin time and prothrombin time. In several mouse hemostasis and thrombosis models, NGAL overexpression or IV administration promoted coagulation and hemostasis and aggravated thrombosis, whereas NGAL knockout or treatment with anti-NGAL monoclonal antibody significantly prolonged bleeding time and alleviated thrombus formation. Notably, NGAL knockout prolonged mouse tail bleeding time or artery occlusion time to over 40 or 60 minutes, respectively, resembling uncontrollable bleeding and clotting disorder seen in hemophilic mice. Furthermore, anti-NGAL monoclonal antibody treatment markedly reduced the formation of blood clots in inflammation-induced thrombosis models. Collectively, these findings unveil a previously unidentified role of NGAL in the processes of coagulation, hemostasis, and thrombosis, as well as the cross talk between innate immunity, inflammation, and coagulation. Thus, modulating NGAL levels could potentially help balance thrombotic and hemorrhagic risks.

1 March 2022 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
MFMingqian Fang
Mingqian Fang
XTXiaopeng Tang
Xiaopeng Tang
JZJuan Zhang
Juan Zhang
ZLZhiyi Liao
Zhiyi Liao
GWGan Wang
Gan Wang
Ren LaiRen Lai
Ren Lai
Significance: An immunosuppressant protein (MTX), which facilitates virus infection by inhibiting leukotriene A 4 hydrolase (LTA 4 H) to produce the lipid chemoattractant leukotriene B 4 (LTB 4 ), was identified and characterized from the submandibular salivary glands of the bat Myotis pilosus . To the best of our knowledge, this is a report of an endogenous LTA 4 H inhibitor in animals. MTX was highly concentrated in the bat salivary glands, suggesting a mechanism for the generation of immunological privilege and immune tolerance and providing evidence of viral shedding through oral secretions. Moreover, given that the immunosuppressant MTX selectively inhibited the proinflammatory activity of LTA 4 H, without affecting its antiinflammatory activity, MTX might be a potential candidate for the development of antiinflammatory drugs by targeting the LTA 4 -LTA 4 H-LTB 4 inflammatory axis.

9 June 2025 in Journal of Thrombosis and Haemostasis
Verified
Journal Article
Closed access
MYMusan Yan
Musan Yan
YWYuewei Wang
Yuewei Wang
LNLiyuan Niu
Liyuan Niu
SWShaoying Wang
Shaoying Wang
HYHaichu Yu
Haichu Yu
CLCHANGJIANG LI
CHANGJIANG LI

2 April 2026 in Blood
Verified
Journal Article
Closed access
RCRuomei Cheng
Ruomei Cheng
XTXiaopeng Tang
Xiaopeng Tang
XHXiaoshan Huang
Xiaoshan Huang
XDXudong Dong
Xudong Dong
YCYifan Chen
Yifan Chen
Ren LaiRen Lai
Ren Lai
Venous thromboembolism (VTE) remains a leading contributor to maternal morbidity and mortality during pregnancy and the immediate postpartum period. Although pregnancy is recognized as a hypercoagulable state, the molecular mechanisms underlying this prothrombotic shift remain incompletely characterized. In this study, lactoferrin was identified as an enhancer of coagulation factor XIa (FXIa) activity. Elevated plasma concentrations of lactoferrin were observed in pregnant women and found to be estrogen dependent, mediated through estrogen response elements (EREs) within the lactoferrin gene promoter. In murine models, pregnancy-induced thrombotic pathology was ameliorated by either genetic knockout of lactoferrin or pharmacological blockade using HS9, a peptide that selectively inhibits lactoferrin-mediated potentiation of FXIa. Notably, HS9 (1 mg/kg) exhibited a substantially reduced hemorrhagic profile compared with low-molecular-weight heparin. These findings identify lactoferrin as a physiological modulator of gestational hypercoagulability and implicate it as a potential therapeutic target for pregnancy-associated VTE, with the capacity to reduce thrombotic risk while preserving hemostatic integrity.

10 January 2026 in Natural Products and Bioprospecting
Verified
Journal Article
Open access
PDF file
LNLiyuan Niu
Liyuan Niu
CLChuanfeng Liu
Chuanfeng Liu
SWShaoying Wang
Shaoying Wang
QYQikai Yin
Qikai Yin
SLShiping Lin
Shiping Lin
YWYuewei Wang
Yuewei Wang
Thrombosis pathogenesis is closely linked to dysregulated lipid metabolism and inflammatory processes. However, the direct regulatory role of mevalonate pathway within the coagulation cascade is still not well understood. This study aimed to elucidate the regulatory effects of mevalonic acid (MVA) on the coagulation system. The effects of MVA on coagulation were measured by recalcification. Enzymatic kinetic analysis and natural substrate hydrolysis assays were performed to identify the coagulation target of MVA. Mice bleeding and thrombosis models were applied to evaluate the effects of MVA administration on hemostasis and thrombosis. Our current study reveals that MVA significantly accelerates plasma coagulation through potentiating the procoagulant activity of FXa, without influencing the platelet aggregation. Studies showed that MVA administration substantially shortened activated partial thromboplastin time, prothrombin time, and reduced bleeding time in both tail bleeding and saphenous vein injury models. Furthermore, using ferric chloride-induced thrombosis, deep vein thrombosis and cerebral infarction models, we observed that MVA markedly potentiated thrombus formation and stroke. Our findings establish for the first time that MVA directly regulates FXa procoagulant activity, while also suggesting potential crosstalk between lipid metabolic pathways and inflammatory signaling in coagulation modulation. These results provide novel mechanistic insights into coagulation abnormalities associated with metabolic disorders such as atherosclerosis and diabetes, highlighting the mevalonate pathway as a potential therapeutic target for thrombotic complications. Graphical Abstract

4 May 2026 in Blood
Verified
Journal Article
Closed access
SLShiping Lin
Shiping Lin
YYYuanjie Yin
Yuanjie Yin
SWShaoying Wang
Shaoying Wang
CLChuanfeng Liu
Chuanfeng Liu
MYMusan Yan
Musan Yan
XTXiaopeng Tang
Xiaopeng Tang
Inflammation and coagulation are intricately linked. Although some studies have documented pro-inflammatory drivers of coagulation, the role of anti-inflammatory cytokines and the underlying mechanisms in the modulation of coagulation, platelet function, and thrombosis remain poorly characterized. In this study, we demonstrated that interleukin-4 (IL-4), an anti-inflammatory cytokine, plays a crucial role in regulating platelet function and thrombus formation. IL-4 inhibited collagen-induced intracellular calcium mobilization, P-selectin expression, ATP release, integrin αIIbβ3 activation, platelet spreading, and platelet aggregation. IL-4 binds to residues 38-46 within GPVI's extracellular collagen-binding domain and suppresses downstream signaling by inhibiting phosphorylation of phospholipase Cγ2 and protein kinase C. A GPVI-derived interfering peptide (RR9) binding to IL-4 disrupted the IL-4-GPVI complex and reversed the inhibitory effects of IL-4 on platelets. In vivo, IL-4 overexpression or intravenous administration inhibited platelet intracellular calcium mobilization, ATP release, and aggregation, prolonged bleeding time, and attenuated both arterial and venous thrombosis. Conversely, IL-4 knockout, anti-IL-4 antibody treatment, or RR9 treatment enhanced platelet reactivity, promoted hemostasis, and aggravated thrombosis. Our findings reveal that IL-4 negatively regulates platelet function through direct interaction with GPVI, thereby facilitating crosstalk among inflammation, hemostasis, and thrombosis. Therefore, modulating IL-4 levels provides a novel strategy for treatment of thrombotic disorders.